Status:
UNKNOWN
Outcomes Study of Glycosylated Hemoglobin Control in Cox-Maze IV During Cardiac Surgery
Lead Sponsor:
Kun Hua
Collaborating Sponsors:
Peking University People's Hospital
Peking University International Hospital
Conditions:
Cardiac Surgery
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In recent years, a growing body of research has shown that diabetes plays an important role in the development and recurrence of atrial fibrillation. How to achieve the treatment and prevention of rec...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Elective cardiac surgery
- A clear diagnosis of diabetes mellitus, and HbA1c ≥ 7.5% at the time of initial diagnosis and treatment
- Preoperative combination of persistent or long-term persistent atrial fibrillation
Exclusion
- Emergency surgery or limited-term surgery
- Previous cardiac surgery
- Left atrial diameter \> 65 mm
- Serum creatine \> 1.8 mg/dL
- Previous severe liver disease
- Pregnant or planning to become pregnant
- Have a malignant tumor
Key Trial Info
Start Date :
May 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT05374655
Start Date
May 15 2022
End Date
August 31 2024
Last Update
April 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, China